Hala Alshayeb1, Arif Showkat, Barry M Wall, Geeta G Gyamlani, Valentin David, L Darryl Quarles. 1. University of Tennessee Health Science Center (A.S., B.M.W., L.D.Q.), Memphis, Tennessee 38103; Veterans Affairs Medical Center (B.M.W., G.G.G.), Memphis, Tennessee 38103; Marshall University (H.A.), Huntington, West Virginia 25701; and University of Miami (V.D.), Miami, Florida 33136.
Abstract
CONTEXT: The optimal circulating concentration of 25(OH) vitamin D is controversial. OBJECTIVE: The aim was to investigate if FGF-23 and 24,25(OH)2D can guide cholecalciferol replacement. DESIGN: Oral cholecalciferol (10,000 IU weekly) administered to subjects with 25(OH)D levels < 20 ηg/mL and eGFR > 60 mL/min/1.73 m(2) (n = 25), chronic kidney disease (CKD) (n = 27), or end stage renal disease (ESRD) (n = 14). SETTING: The study was conducted at the Veterans Affairs clinics. MAIN OUTCOME MEASURE: Serum FGF-23, PTH, 25(OH)D, 1,25(OH)2D, 24,25(OH)2D, calcium, and phosphorous concentrations, and urinary excretion of calcium and phosphorus at baseline and after 8 weeks of treatment. RESULTS: Cholecalciferol treatment increased concentrations of serum 25(OH)D by (19.3 ± 8 ηg/mL, P = .001; 12.2 ± 9 ηg/mL, P = .0001) and 24,25(OH)2D (1.14 ± 0.89 ηg/mL, P = .0024; 1.0 ± 0.72 ηg/mL P = .0002), and reduced serum PTH (-11 ± 21 pg/mL, P = .0292; -42 ± 68 pg/mL, P = .0494) in normal and CKD subjects, respectively. Cholecalciferol increased serum FGF-23 levels only in normal subjects (44 ± 57 ηg/mL, P = .01). Increments in serum 25(OH)D positively correlated with serum FGF-23 and 24,25(OH)2D and negatively correlated with PTH. In ESRD, cholecalciferol administration increased 25(OH)D by (16.6 ± 6.6 ηg/mL P ≤ .05) without changing 24,25(OH)2D, FGF-23 or PTH levels. CONCLUSION: Modest elevations of serum 25(OH)D levels after cholecalciferol treatment are sufficient to induce compensatory degradative pathways in patients with sufficient renal reserves, suggesting that optimal circulating 25(OH)D levels are approximately 20 ηg/mL. In addition, catabolism of 25(OH)D may also contribute to the low circulating vitamin D levels in CKD, since elevations of FGF-23 in CKD are associated with increased 24,25(OH)2D after cholecalciferol administration.
CONTEXT: The optimal circulating concentration of 25(OH) vitamin D is controversial. OBJECTIVE: The aim was to investigate if FGF-23 and 24,25(OH)2D can guide cholecalciferol replacement. DESIGN: Oral cholecalciferol (10,000 IU weekly) administered to subjects with 25(OH)D levels < 20 ηg/mL and eGFR > 60 mL/min/1.73 m(2) (n = 25), chronic kidney disease (CKD) (n = 27), or end stage renal disease (ESRD) (n = 14). SETTING: The study was conducted at the Veterans Affairs clinics. MAIN OUTCOME MEASURE: Serum FGF-23, PTH, 25(OH)D, 1,25(OH)2D, 24,25(OH)2D, calcium, and phosphorous concentrations, and urinary excretion of calcium and phosphorus at baseline and after 8 weeks of treatment. RESULTS:Cholecalciferol treatment increased concentrations of serum 25(OH)D by (19.3 ± 8 ηg/mL, P = .001; 12.2 ± 9 ηg/mL, P = .0001) and 24,25(OH)2D (1.14 ± 0.89 ηg/mL, P = .0024; 1.0 ± 0.72 ηg/mL P = .0002), and reduced serum PTH (-11 ± 21 pg/mL, P = .0292; -42 ± 68 pg/mL, P = .0494) in normal and CKD subjects, respectively. Cholecalciferol increased serum FGF-23 levels only in normal subjects (44 ± 57 ηg/mL, P = .01). Increments in serum 25(OH)D positively correlated with serum FGF-23 and 24,25(OH)2D and negatively correlated with PTH. In ESRD, cholecalciferol administration increased 25(OH)D by (16.6 ± 6.6 ηg/mL P ≤ .05) without changing 24,25(OH)2D, FGF-23 or PTH levels. CONCLUSION: Modest elevations of serum 25(OH)D levels after cholecalciferol treatment are sufficient to induce compensatory degradative pathways in patients with sufficient renal reserves, suggesting that optimal circulating 25(OH)D levels are approximately 20 ηg/mL. In addition, catabolism of 25(OH)D may also contribute to the low circulating vitamin D levels in CKD, since elevations of FGF-23 in CKD are associated with increased 24,25(OH)2D after cholecalciferol administration.
Authors: Clifford J Rosen; Steven A Abrams; John F Aloia; Patsy M Brannon; Steven K Clinton; Ramon A Durazo-Arvizu; J Christopher Gallagher; Richard L Gallo; Glenville Jones; Christopher S Kovacs; JoAnn E Manson; Susan T Mayne; A Catharine Ross; Sue A Shapses; Christine L Taylor Journal: J Clin Endocrinol Metab Date: 2012-03-22 Impact factor: 5.958
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2011-06-06 Impact factor: 5.958
Authors: Miriam G Garcia-Lopes; Roberta Pillar; Maria Ayako Kamimura; Lillian A Rocha; Maria Eugênia F Canziani; Aluízio B Carvalho; Lilian Cuppari Journal: Ann Nutr Metab Date: 2012-08-07 Impact factor: 3.374
Authors: Zona Batacchi; Cassianne Robinson-Cohen; Andrew N Hoofnagle; Tamara Isakova; Bryan Kestenbaum; Kevin J Martin; Myles S Wolf; Ian H de Boer Journal: Clin J Am Soc Nephrol Date: 2017-08-02 Impact factor: 8.237
Authors: Peter L Havens; Charles B Stephensen; Marta D Van Loan; Gertrud U Schuster; Leslie R Woodhouse; Patricia M Flynn; Catherine M Gordon; Cynthia G Pan; Brandy Rutledge; D Robert Harris; Georgine Price; Alyne Baker; William A Meyer; Craig M Wilson; Rohan Hazra; Bill G Kapogiannis; Kathleen Mulligan Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Myles Wolf; Matthew R Weir; Nelson Kopyt; Roslyn B Mannon; Jon Von Visger; Hongjie Deng; Susan Yue; Flavio Vincenti Journal: Transplantation Date: 2016-01 Impact factor: 4.939
Authors: Christian Trummer; Verena Schwetz; Marlene Pandis; Martin R Grübler; Nicolas Verheyen; Martin Gaksch; Armin Zittermann; Winfried März; Felix Aberer; Julia Steinkellner; Claudia Friedl; Vincent Brandenburg; Jakob Voelkl; Ioana Alesutan; Barbara Obermayer-Pietsch; Thomas R Pieber; Andreas Tomaschitz; Stefan Pilz Journal: Eur J Nutr Date: 2018-03-30 Impact factor: 5.614